v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Research and development $ 1,643,375 $ 966,110
General and administrative 1,578,442 757,281
Total operating expenses 3,221,817 1,723,391
Loss from operations (3,221,817) (1,723,391)
Interest income 596,845 82,165
Net loss (2,624,972) (1,641,226)
Other comprehensive income (loss):    
Foreign currency translation gain (loss) 1,239 (835)
Unrealized gain on investments 346 19,198
Comprehensive loss $ (2,623,387) $ (1,622,863)
Net loss per share:    
Basic and diluted (in dollars per share) $ (0.38) $ (0.51)
Weighted average shares outstanding:    
Basic and diluted** (in shares) [1] 6,987,381 3,195,963
[1] Information pertaining to number of shares outstanding and per share data gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024.